Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 18, 2020

View Archived Issues

Pfizer studies PF-06939926 in phase III for DMD

Pfizer conducts phase I study of PF-07248144 in advanced or metastatic solid tumors

Psychedelic analogue has therapeutic potential

Discovery and preclinical evaluation of a new sGC stimulator for hypertension treatment

ONK Therapeutics signs option license agreements to strengthen NK cell therapy pipeline

Phase II data on AB-023 support use in prevention of device-associated thrombosis

Chordia Therapeutics reports preclinical data for MALT1 inhibitor

Vasomune initiates first-in-human study of AV-001 as potential therapy for COVID-19 and ARDS

Phase I/II data shows therapeutic activity of OTO-413 across multiple speech-in-noise hearing tests

Benlysta approved as the first therapy for adult patients with active lupus nephritis in the U.S.

HSF1 inhibition directly targets treatment-resistant prostate cancer

Results from first-in-human trial of BCMA-targeted ADC MEDI-2228 presented

VioGen Biosciences patents new PIKfyve inhibitors

Agios Pharmaceuticals synthesizes new MAT2A inhibitors

Angex Pharmaceutical presents new PRMT5 inhibitors

Ideaya Biosciences discloses POLH inhibitors

STP-938, a novel CTPS1 inhibitor with activity in hematological malignancies

New hMPV-derived vaccines presented by Valneva

Phase II trials of ALX-629 begin in COVID-19, atopic asthma and psoriasis

EDP-1503 plus pembrolizumab safe and well-tolerated in TNBC patients

First-in-human data presented for AB-928 with or without IPI-549 in patients with cancer

Albireo starts phase III trial of odevixibat in Alagille syndrome

Shionogi initiates phase I/II study in Japan with COVID-19 vaccine candidate

FDA clears IND for AlloVir's ALVR-106 to treat severe respiratory viral infections

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...